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Abstract
Introduction: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in Poland and worldwide.
Cost-of-illness studies (analysing total, direct and indirect costs) are studies aimed to determine the economic burden of a
disease. Acute exacerbations and hospitalisation are the major cost drivers in COPD. The aim of the study was to estimate
the direct costs of COPD treatment in the setting of specialist outpatient care from the societal perspective.
Material and methods: Chronic obstructive pulmonary disease costs were estimated from a compilation of data: medical
records of patients managed at 8 specialist outpatient clinics and 5 teaching hospitals in Poland between 2007 and 2008.
The direct costs, resulting from chronic treatment and treatment of acute exacerbations in the outpatient setting, were
calculated using the bottom-up approach on the basis of data collected by pulmonary specialists at outpatient clinics. The
mean cost of acute exacerbation managed in the inpatient setting was derived from a multicentre Polish study in which five
clinical centres participated.
Results: The total cost per patient per year was 4027.82 zlotys (1007 euro) and included the cost of chronic treatment in the
amount of 2423.57 zlotys (606 euro) plus the cost of treatment of an acute exacerbation in the outpatient setting in the
amount of 421.16 zlotys (105 euro) plus the cost of treatment of an acute exacerbation in the inpatient setting in the amount
of 1183.09 zlotys (296 euro).
Conclusion: Treatment of COPD in poses a considerable economic burden on the Polish society.
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Introduction
Epidemiological studies estimate the average
prevalence of chronic obstructive pulmonary di-
sease (COPD) in the general population at 10% [1–
5]. According to a widespread belief, a certain un-
defined number of patients remain undiagnosed,
which results from limited access to spirometry
and very mild clinical symptoms, particularly in
the early stages of the disease [3, 6]. The costs of
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Table 1. Comorbidities in COPD  (% of patients)
Diabetes 8
Hypertension 42
Coronary artery disease 24
Pulmonary thromboembolic disease 7
Psychiatric disorders (depression, anxiety, aleksythymia Not
examined
Table 2. Type of employment and sick leaves due to
COPD exacerbation  (% of patients)
Full employment 6
Part time employment 4
Retired 60
Pension 31
Sick Leave 6
respiratory diseases in the European Union are
estimated at 6% of the health care budget, 56% of
which being attributable to patients with COPD [5].
COPD is therefore not only a considerable public
health problem but also a significant economic
burden for each country’s budget [1, 3, 4, 7, 8]. A
comparison of this burden between individual co-
untries is difficult due to the differences in health
care systems, economic conditions and health-
care outlays. Cost-of-illness studies are aimed to deter-
mine the economic impact of a disease by measuring
direct and indirect costs without taking into account
issues related to treatment efficacy [9–11]. Measure-
ments of costs show the financial burden to the state
(state institutions) from the societal point of view and
the cost of illness in the individual patient. They are
also significant for the pharmaceutical industry, as
they allow to assess the market and treatment stan-
dards in specific diseases. Sometimes studies of co-
sts raise controversy, as they are used for making de-
cisions in the process of defining priorities in access
to health care resources [10, 11].
The aim of our study was to estimate direct
costs of COPD in patients receiving specialist
outpatient care in Poland from the societal per-
spective.
Material and methods
The study included 69 men and 39 women
(mean age 69 ± 9.5 years) managed at 8 outpatient
clinics providing specialist outpatient care (7 cli-
nics from the Mazovian province and 1 clinic from
the Silesian province). This was a prospective stu-
dy conducted between 2007 and 2008. Costs were
calculated on the basis of a compilation of data
obtained from two sources:
1) the mean cost of chronic treatment of COPD
and treatment of an acute exacerbation in the
outpatient setting was derived from the patient
records collected by pulmonary specialists in the
participating clinics. The data included: demo-
graphic data, number of visits, diagnostic and la-
boratory tests, medication use, number of acute
exacerbations managed in the outpatient and in
the inpatient settings, use of home oxygen thera-
py, and influenza vaccinations. Additional para-
meters that were assessed included: transport of
the patient to the clinic, line of employment, and
the number and duration of sick leaves;
2) the mean cost of treatment of an acute exacer-
bation in the inpatient setting was derived
from a previously published Polish multicen-
tre study [12, 13].
Unit costs were derived from the catalogu-
es of the National Health Fund. Medication co-
sts, defined by gross retail prices, were derived
from the lists published by the Minister of He-
alth in force in 2008. The mean cost of home
oxygen therapy per each analysed patient was
calculated on the basis of reconciliations with
the National Health Fund, assuming that 1 re-
conciliation point was equivalent to 1 day of
oxygen therapy.
Statistical analysis
The study population was characterised using
descriptive statistics: mean values and standard
deviations were calculated for quantitative varia-
bles and absolute and relative frequencies were
calculated for qualitative variables. Health care re-
source utilisation and the individual components
of the costs of illness were presented as a mean cost
per patient per year. The 95% confidence intervals
(CI) were calculated using the bootstrapping appro-
ach [14]. Confidence intervals were not calculated
for aggregate data.
Results
The age distribution in the study population
was as follows: 2% of the patients were aged 40–
50 years, 38% were aged 51–65 years, 52% were
aged 66–80 years and 8% were aged 81 years or
more. Current smokers and never-smokers accoun-
ted for 39% and 10% of the subjects, respectively.
Patients with mild (stage I), moderate (stage II) and
severe to very severe (stages III or IV) disease ac-
counted for 9.2%, 47.2% and 43.5% of the study
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population, respectively. Table 1 lists the co-mor-
bidities in COPD. The most common ones were
cardiovascular diseases (coronary artery disease
and hypertension), although diabetes mellitus was
present in 8% and pulmonary embolism was pre-
sent in about 7% of the patients. Psychiatric co-
morbidities, such as depression, were not investi-
gated in our study. According to Table 2, 91% of
the patients managed at the specialist outpatient
clinics were old-age or disability pensioners and
only 6% took sick leave during acute exacerbation
of their disease. Patients arrived at the clinic on
public transport (56%) or in their own car (33%)
(Table 3). More than 90% of the patients with
COPD were managed with short-acting b2-agonists
(SABAs) or long-acting b2-agonists (LABAs), 84.3%
received anticholinergic agents and 61.1% received
inhaled glucocorticosteroids (Table 4). During an
Table 3. Type of transport used to get to the outpatient
clinic (% of patients)
Ambulance 1
Medical transport 0
Public transport 56
Private car 33
Taxi 1
Train/ Coach bus 3
Table 4. Drugs in the treatment of chronic COPD and
during outpatient exacerbation (% of patients)
Drugs classes Chronic treatment Treatment of acute
of COPD exacerbations of COPD
Oral Corticosteroids 2.8 43.5
LABA, SABA 91.7 72.2
Inhaled Corticosteroids 61.1 76.9
Anticholinergics 84.3 74.1
Xanthines 59.3 52.7
Mucolitics 32 47.2
Antibiotics 4.5 84.3
LABAs — long-acting b2-agonists; SABAs — short-acting b2-agonists
Table 5. Medication costs in the chronic treatment of COPD and in the treatment of acute exacerbations of COPD (in zlotys;
95% CI)
Chronic treatment Treatment of an acute Treatment of an
(30 days)  exacerbation in the outpatient acute exacerbation
setting followed by 14-day treatment in the inpatient setting
following the exacerbation
Medication cost 147.24 170.81 426.37
(126.54–172.67) (152.3–189.91) (312.83–559.81)
acute exacerbation treated in the outpatient setting
there was an increase in the number of patients
receiving oral glucocorticosteroids, antibiotics,
inhaled glucocorticosteroids and mucolytics. The
mean cost of medication was 147.24 zlotys for chro-
nic treatment (per 30-day period), 170.81 zlotys for
an acute exacerbation treated in the outpatient
setting and 426.00 zlotys for an acute exacerbation
treated in the inpatient setting (Table 5). Patients
in Poland attend an average of 2.94 outpatient vi-
sits, the mean number of exacerbation-free days is
333.1, an average of 57.1% of the patients undergo
influenza vaccination and 11.4% of the doctors
performing home visits prescribe home oxygen
therapy (Table 6). There are 1.27 and 0.24 of acute
exacerbations treated in the outpatient and in the
inpatient setting, respectively, per one patient with
COPD. Table 6 summarises the calculated total cost
per patient per year broken down into component
costs: cost of chronic treatment, cost of treatment
of acute exacerbations in the outpatient setting and
cost of treatment of acute exacerbations in the in-
patient setting.
Discussion
In pharmacoeconomics, the costs of an illness
are divided into direct medical costs, direct non-
medical costs and indirect costs, which are asso-
ciated with the loss of productivity [9–11, 15].
Direct medical costs comprise: hospitalisa-
tions, visits at medical emergency facilities, medi-
cal staff fees, medication, drug dosing devices (ne-
bulisers, spacers), instruction and education. Di-
rect non-medical costs are difficult to analyse, as
they are outside the health care system and result,
for instance, from the deterioration of the finan-
cial standing of the patient’s spouse and children
due to the loss of ability to earn a living by the
patient. Indirect costs of an illness comprise: disa-
bility pensions, old-age pensions, sick leaves and
premature mortality. Two approaches of estimating
indirect costs are currently used: the human-capi-
tal approach and the friction cost approach. Accor-
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ding to the human-capital approach, the indirect
cost comprises the number of days off work per
patient resulting from the loss of gross domestic
product. The friction cost approach, on the other
hand, assumes gross domestic product loss until
the outgoing employee is replaced. In this appro-
ach, indirect costs are lower than those calculated
using the human-capital approach. While neither
of the approaches has been shown superior so far,
vast differences are seen in the results of research
studies.
Our study was based on data from two other
studies, one of outpatient care and the other of
inpatient care. In both studies, data were collec-
ted prospectively but the idea to carry out the ana-
lysis appeared after the commencement of data
collection, which is why the analysis is retrospec-
tive in nature.
It was shown that the mean total cost of treat-
ment of a COPD patient in Poland in 2008 was 4027
zlotys. It was a selected group of patients receiving
specialist care, most of whom were being treated
in accordance with the COPD management stan-
dards [5, 16]. Anticholinergic agents were received
by 84% of the patients, SABAs/LABAs by 91.7%,
inhaled glucocorticosteroids by 61% and theophyl-
line derivatives by 59%. Of note is the high cost of
medications used in chronic treatment, which cost
is shown from the societal perspective and nears
an average of 150 zlotys a month. It should be
emphasised that this is the cost of medications used
for the treatment of COPD in patients who are com-
monly burdened with numerous co-morbidities.
The costs of treatment of COPD in Poland dif-
fer from those in other countries, as shown in a
large Confronting COPD Survay study [17]. For in-
stance, the annual direct costs were 614 euro in
the Netherlands, 1255 euro in Italy, 3196 euro in
Spain and 4119 dollars in the United States. A si-
milarly high variability has been shown with re-
spect to the indirect costs of the disease, which
accounted for 4% of the total costs in Italy but as
much as 60% in France. In Poland, the indirect
costs of COPD are not high because 91% of the
medical care is provided to old-age or disability
pensioners, who do not contribute to gross dome-
stic product. Only 6% of COPD patients in Poland
take sick leave during periods of exacerbation.
Published data show that most of the indirect
medical costs are costs of treatment of acute exa-
cerbations in the inpatient setting [12, 17–20].
Multicentre studies conducted in Poland showed
that the mean cost of treatment of acute exacerba-
tions of COPD in the inpatient setting was 4871.55
zlotys, which suggests a considerable underestima-
tion of this procedure by the National Health Fund.
This analysis also reveals the faults of the health
care system. In contrast to Western European co-
untries, the Polish health care system lacks proce-
dures for the treatment of acute exacerbations at
home or at emergency facilities [18, 20]. Because
of that the patient with an acute exacerbation of
COPD is most commonly hospitalised irrespecti-
ve of the severity of the exacerbation. In the con-
text of the assessed costs of illness, the initiative
to create a model of integrated care provided to
patients with COPD in Poland seems very appe-
aling [21]. In 2008 in the US, the average cost of
an acute exacerbation was estimated at 3439 dol-
lars, although the cost of a severe acute exacerba-
tion, which was defined as the need for hospitali-
sation or death, was estimated at as much as 11,261
dollars [22]. Patients without acute exacerbations
cost the payor half of what patients with acute
exacerbations do.
Several aspects of diagnostic evaluation and
treatment of patients with COPD rarely taken into
consideration in everyday medical practice war-
rant attention. In Poland, despite the existence of
relevant management standards (The Global Ini-
tiative for Chronic Obstructive Lung Disease), vir-
tually no respiratory rehabilitation services are
provided in the outpatient setting, which is why
Table 6. Mean cost of COPD per patient per year in Poland
(in zlotys)
Acute exacerbations treated in the outpatient setting
Number of acute exacerbations per year 1.27
Cost of medications and diagnostic tests 320.44
Cost of medical visits 100.71
Cost of one acute exacerbation 252.03
Total cost of acute exacerbations treated
in the outpatient setting 421.16
Acute exacerbations treated in the inpatient setting
Number of acute exacerbations per year 0.24
Cost of one acute exacerbation 4871.55
(4114.60–5712.80)
Total cost of acute exacerbations treated
in the inpatient setting 1183.09
Chronic treatment
Cost of medications and diagnostic tests 1650.15
Cost of medical visits 147.14
Cost of influenza vaccinations 45.71
Cost of home oxygen therapy 580.57
Total cost of chronic treatment of COPD 2423.57
Total cost of COPD per patient per year 4027.82
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this method of treatment could not be included in
the analysis. In addition, the evaluation of costs
in patients with COPD rarely takes into account
mental and emotional problems and problems as-
sociated with the worsening of health-related qu-
ality of life (HRQoL) [23–27], while quality-of-life
studies in patients with COPD are gaining an in-
creasing significance as a supplementary element
in the evaluation of the patient’s clinical condition,
the effects of education and treatment provided to
the patient and the clinical evaluation of medica-
tions and the acceptance of the treatment by the
patient [23–27].
A study by Grabowska-Krawiec showed that
a considerable percentage of patients with COPD
suffer from depression or alexithymia [25]. The
elderly are particularly faced with significantly
greater problems with the regulation of emotions
compared to healthy individuals and are more
often alexithymic, which may be associated with
the difficulties in the doctor-patient relationship.
This relationship is very important, as adhe-
rence to treatment generates a 44% decrease in the
number of acute exacerbations and a 60% decre-
ase in mortality [28, 29]. According to the TORCH
(Towards a Revolution in COPD) study, 80% of the
patients adhered to inhaled therapy, while 20% did
not, and in 8% of the patients adherence fell be-
low 60% of the prescribed doses of inhalation the-
rapy [29]. The study also showed that adherence
to treatment does not depend on the severity of the
disease, but is greater in men and in patients with
a more intense perception of dyspnoea. A compre-
hensive assessment of chronic treatment requires
therefore several years of follow-up in the setting
of phase IV studies, when the clinical effectiveness,
safety and adherence to treatment are being asses-
sed in real-life conditions. Results of a Dutch ana-
lysis showed that 54% of the patients started their
treatment of COPD with anticholinergic agents,
47% with LABAs and over 40% with fixed-dose
combinations [30]. Three years later, however, 39–
57% of the patients were no longer taking any
medication.
Conclusion
Assessment of costs should be one of the ar-
guments in the discussion on the improvement of
care provided to patients suffering from COPD.
Cost-of-illness studies in COPD should contribute
to the increased awareness of the role of these co-
sts, including, first of all, costs of acute exacerba-
tions, among decision-makers in the health care
system. A realistic assessment of costs requires
taking into consideration such aspects as treatment
compliance and treatment persistence.
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